Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

IF 1.9 4区医学 Q3 HEMATOLOGY

Transfusion Medicine and Hemotherapy Pub Date : 2024-10-01 eCollection Date: 2025-02-01 DOI:10.1159/000540962

Fenja Gierschek, Juliane Schlueter, Ines Kühnel, Frederik Fabian Feigl, Dominik Schmiedel, Maren Prüfer, Leon Buchinger, Adelheid Cerwenka, Claudia Cappel, Sabine Huenecke, Ulrike Köhl, Winfried S Wels, Evelyn Ullrich

{"title":"Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.","authors":"Fenja Gierschek, Juliane Schlueter, Ines Kühnel, Frederik Fabian Feigl, Dominik Schmiedel, Maren Prüfer, Leon Buchinger, Adelheid Cerwenka, Claudia Cappel, Sabine Huenecke, Ulrike Köhl, Winfried S Wels, Evelyn Ullrich","doi":"10.1159/000540962","DOIUrl":null,"url":null,"abstract":"Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML.Summary: Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC).Key messages: In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future.","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"42-60"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813277/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine and Hemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540962","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML.

Summary: Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC).

Key messages: In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future.

查看原文本刊更多论文

增强自然杀伤细胞对抗急性髓系白血病：CAR-NK细胞治疗的观点。

背景：急性髓系白血病（AML）是一种侵袭性血液系统恶性肿瘤，复发率高，治疗选择有限。基于自然杀伤（NK）细胞的免疫疗法有可能改善AML患者的预后。摘要：最近的临床前研究和早期临床试验旨在通过嵌合抗原受体（car）选择性靶向AML细胞来增强NK细胞固有的抗白血病特性。此外，NK细胞和CAR-NK细胞可以与其他治疗方式结合或进一步改造以克服免疫抑制微环境，以及AML原细胞和白血病起始细胞（LIC）的治疗耐药性。在这篇综述中，我们总结了来自不同细胞来源的细胞因子刺激或基因工程NK细胞治疗AML的临床前研究及其转化为早期临床试验。我们还概述了在不久的将来可能实施的创新NK细胞为基础的治疗方法的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion Medicine and Hemotherapy 医学-免疫学

CiteScore

4.00

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal is devoted to all areas of transfusion medicine. These include the quality and security of blood products, therapy with blood components and plasma derivatives, transfusion-related questions in transplantation, stem cell manipulation, therapeutic and diagnostic problems of homeostasis, immuno-hematological investigations, and legal aspects of the production of blood products as well as hemotherapy. Both comprehensive reviews and primary publications that detail the newest work in transfusion medicine and hemotherapy promote the international exchange of knowledge within these disciplines. Consistent with this goal, continuing clinical education is also specifically addressed.